Page last updated: 2024-08-23

bezafibrate and Hyperlipemia

bezafibrate has been researched along with Hyperlipemia in 143 studies

Research

Studies (143)

Timeframe	Studies, this research(%)	All Research%
pre-1990	31 (21.68)	18.7374
1990's	43 (30.07)	18.2507
2000's	58 (40.56)	29.6817
2010's	10 (6.99)	24.3611
2020's	1 (0.70)	2.80

Authors

Authors	Studies
Brown, PJ; Henke, BR; Sternbach, DD; Willson, TM	1
Chen, Y; Mu, T; Shao, Q; Tong, N; Yang, X; Zhang, X; Zhang, Y; Zhou, Y	1
Casado, TC; De Marco, V; Florio, JC; Gilor, C; Nakandakare, ER; Noronha, KSM; Santos, EZ	1
Chen, W; Fan, S; Jin, X; Wang, L; Xie, X; Xue, N	1
Al-Hiari, Y; Al-Qirim, T; Jarab, A; Shattat, G; Sheikha, GA; Sweidan, K	1
Anzivino, C; Bertolotti, M; Carulli, L; Carulli, N; Corna, F; Del Puppo, M; Gabbi, C; Kienle, MG; Loria, P; Pellegrini, E; Ricchi, M; Zambianchi, L	1
Abourbih, S; Eisenberg, MJ; Filion, KB; Genest, J; Joseph, L; Pilote, L; Poirier, P; Rinfret, S; Schiffrin, EL	1
Al-Hiari, Y; Al-Qirim, T; El-Huneidi, W; Shahwan, M; Shattat, G; Sweidan, K	1
Al-Hiari, Y; Al-Qirim, R; Al-Qirim, T; El-Huneidi, W; Shahwan, M; Shattat, G; Sheikha, GA	1
Goto, T; Kanzaki, N; Kawada, T; Kimura, R; Moriyama, T; Murakami, Y; Murota, K; Niiya, S; Takahashi, N; Yamada, Y	1
Al-Hiari, Y; Al-Qirim, T; El-Huneidi, W; Hikmat, S; Shattat, G; Sheikha, GA	1
Hohendorff, B; Mühldorfer-Fodor, M; Prommersberger, KJ; Schmitt, R; Wagner, M	1
Critchley, WR; Shah, MK; Shaw, SM; Williams, SG; Yonan, N	1
Athyros, V; Bairaktari, E; Elisaf, M; Ganotakis, E; Rizos, E; Seferiades, C; Tsimihodimos, V	1
Kotake, H	1
Hayakawa, T; Inotsume, N; Sekiguchi, M; Sekiya, S; Shimoyama, K	1
Bortolini, M; Farnier, M; Freudenreich, MO; Gonasun, L; Isaacsohn, JL; Salko, T; Troendle, AJ	1
Backes, JM; Moriarty, PM	1
Barberá, G; Chacón, P; Hernández, C; Lecube, A; Lima, J; Simó, R	1
Alder, R; Berry, JA; Lookinland, S; Williams, M	1
Fujioka, Y; Kim, JI; Saito, K; Tsujino, T; Yokoyama, M	1
Boden, WE	1
Dejager, S; Farnier, M; Gonasun, L; Isaacsohn, JL; Salko, T; Troendle, AJ	1
Itoh, M; Kitamura, T; Niho, N; Noda, T; Shoji, Y; Sugimura, T; Takahashi, M; Wakabayashi, K	1
Anand, IS; Chodorowski, Z; Kaletha, K; Nagel-Starczynowska, G; Rybakowska, I	1
Mal', GS	1
Ascaso, JF; Felipe Pallardo, L; Fernández-Cruz, A; González Santos, P; Hernández Mijares, A; Mangas Rojas, A; Millán, J; Pedro-Botet, J; Pérez-Jiménez, F; Pía, G; Pintó, X; Plaza, I; Rubiés-Prat, J	1
Malcolm, J; Meggison, H; Sigal, R	1
Brennan, SO; George, PM; Maghzal, GJ	1
Hata, T; Ishikawa, K; Kitagawa, Y; Ohta, T; Shinohara, Y; Tomiyasu, H; Yamamoto, M	1
Calza, L; Chiodo, F; Colangeli, V; Manfredi, R; Pocaterra, D; Sebastiani, T; Tampellini, L	1
Fisman, EZ; Motro, M; Tenenbaum, A	1
Arai, D; Ichikawa, H; Kawamura, M; Kuriki, A; Sugie, M	1
Arístegui, R; Artieda, M; Cenarro, A; Civeira, F; Díaz, C; Gañán, A; Gonzalvo, C; Meriño-Ibarra, E; Pocoví, M; Sol, JM	1
Elisaf, MS; Mikhailidis, DP; Milionis, HJ	1
Fukushima, H; Jinnouchi, H; Koga, H; Kugiyama, K; Ogawa, H; Sakamoto, T; Sugiyama, S; Watanabe, K; Yoshimura, M	1
Mutoh, M; Niho, N; Wakabayashi, K	1
Adachi, Y; Fujita, N; Horiike, S; Iwasa, M; Kai, M; Kaito, M; Konishi, M; Sugimoto, R; Tanaka, H; Watanabe, S	1
Gondoh, K; Imamura, K; Miyakoda, K; Mukasa, M; Ono, T; Sata, M; So, A	1
Arnaout, A; Malcolm, J; Sigal, R	1
Fujioka, D; Kawabata, K; Kitta, Y; Kobayashi, T; Kodama, Y; Kugiyama, K; Mende, A; Nakamura, T; Obata, JE; Saito, Y; Takano, H; Umetani, K	1
Kawakami, M; Kawano, M; Senba, H	1
Hidaka, H; Hongo, M; Ikeda, U; Kinoshita, O; Kumazaki, S; Mawatari, E; Takahashi, M; Tsutsui, H; Yazaki, Y	1
Honková, M; Kunesová, M; Mares, P; Skorepa, J; Zeman, M	1
Bartosiewicz, W; Ilińska-Debniak, K; Stryjek-Kamińska, D; Szczepanik, Z	1
Baker, F; Walls, J; Williams, AJ	1
Chiang, HL; Chou, TY; Ho, LT; Kwok, CF; Tsai, H	1
Rüth, E; Vollmar, J	1
Holler, HD; Janka, HU; Mehnert, H; Standl, A	1
Lang, PD; Vollmar, J	1
Grützmacher, P; Lang, W; Scheuermann, E	1
Bode, G; Ditschuneit, H; Hutt, V; Klör, HU; Wechsler, JG	1
Stratmann, FW	1
Anderson, P; Norbeck, HE	2
Hofmann, H; Holler, HD; Stratmann, FW	1
Alcala, J; Blanco, J; Espino, A; Hidalgo, L; Jansen, S; Jiménez-Perepérez, JA; López-Miranda, J; Pérez-Jiménez, F; Prada, JL; Rodríguez, M	1
Alberti, KG; Dyer, RG; Laker, MF; Stewart, MW	1
Dujovne, CA; Lozada, A	1
Akabane, S; Inoue, I; Ishii, J; Katayama, S; Kawazu, S; Negishi, K; Suzuki, M; Takahashi, K	1
Bedani, PL; Gilli, P; Perini, L	1
Hutchesson, AC; Jones, AF; Moran, A	1
Arizon, JM; Blanco, J; Concha, M; Espino, A; Hidalgo, L; Jimenez-Pereperez, JA; Lopez-Miranda, J; Perez-Jimenez, F; Valles, F; Zambrana, JL	1
Boni, M; De Sio, G; Mazzanti, L; Monteburini, T; Polenta, M; Testa, I	1
Capps, NE	1
Barbir, M; Galloway, D; Hunt, BJ; Ilsley, C; Mitchell, A; Taylor, A; Yacoub, M	1
Ariad, S; Hechtlinger, V	1
Armitage, M; McLeod, AJ; Warren, RJ	1
Branchi, A; Rovellini, A; Sommariva, D	1
Etti, H; Kondor, P; Pirich, C; Sinzinger, H	1
Fukuo, Y; Kitami, T; Nomoto, T; Terashi, A	1
Seed, M	1
Michigishi, T; Takayama, T; Taki, J; Tonami, N; Tsuji, S	1
Anguita Sánchez, M; Blanco Cerrada, J; Casares Mediavilla, J; Jiménez Perepérez, JA; López Miranda, J; Muñoz Carvajal, I; Pérez Jiménez, F; Vallés Belsúe, F; Zambrana García, JL	1
Grover, S; Hamilton, VH; Lavoie, F; Perreault, S	1
Barradell, LB; Goa, KL; Plosker, GL	1
Fujishlma, M; Iwase, M; Takano, K; Waklsaka, M; Yamamoto, M; Yoshinari, M	1
Jeck, T; Keller, U; Riesen, WF	1
Mir, MA; Oleesky, DA	1
Lakatos, J; Molnár, M; Tóth, K	1
Castro, P; Concha, M; Jimenéz-Perepérez, JA; López-Miranda, J; Montilla, P; Pérez-Jiménez, F; Vallés, F; Velasco, F; Zambrana, JL	1
Båvenholm, P; de Faire, U; Ericsson, CG; Godsland, I; Hamsten, A; Jovinge, S; Nilsson, J; Proudler, A; Tornvall, P	1
Sterna, R	1
Beringer, TR	1
Yamada, M	1
Arizón, JM; Blanco, A; Concha, M; Jansen, S; Jimenéz-Perepérez, JA; López-Miranda, J; Paniagua, JA; Pérez-Jiménez, F; Zambrana, JL	1
Rader, DJ	1
Ganotakis, ES; Jagroop, IA; Mikhailidis, DP; Papadakis, JA; Winder, AF	1
Friedman, M; Gilhar, D; Hoffman, A; Lomnicky, Y; Luria, MH	1
Anyaoku, V; Diamond, JR; Elkeles, RS; Hughes, C; Richmond, W	1
Hannak, M; Lüscher, TF; Noll, G; Spieker, LE	1
Fukuda, M; Ito, S; Lee, R; Ogawa, S; Sato, T; Sugimura, K; Takeuchi, K	1
Gavish, D; Leibovitz, E; Rubinstein, A; Shapira, I	1
Bisicchia, A; Di Salvo, MM; Ferlito, S; Gallina, M; Mugno, F	1
Abdella, N; Akanji, AO; Mojiminiyi, OA	1
Friedman, M; Haimov, T; Hoffman, A; Lomnicky, Y; Luria, MH	1
Durrington, P	1
Ito, Y; Miyashita, Y; Murano, T; Shirai, K; Totsuka, M; Watanabe, H	1
Slobodin, G; Yeshurun, D	1
Miller, M	1
Hirschfield, G	1
Barter, PJ; Dimmitt, SB; Watts, GF	1
Arístegui, R; Canudas, J; Cenarro, A; Civeira, F; Díaz, C; Garcí-Otín, AL; Hernández, G; Masramon, X; Pocoví, M; Sol, JM	1
Fukuhara, S; Kagawa, H; Nagahama, M; Nomura, S; Ozaki, Y	1
Doolman, R; Gavendo, S; Harats, D; Marko, D; Sela, BA; Shaish, A; Yodfat, O	1
Hirano, T; Kazumi, T; Yoshino, G	1
Kawamori, R; Onuma, T	1
Tada, N	1
Beynen, AC; Donker, AJ; Heine, RJ; Rustemeijer, C; Schouten, JA; Voerman, HJ	1
Bargman, JM; Lipscombe, J	1
Hamilton-Craig, I	1
Chiodo, F; Manfredi, R	1
Knight, BL; Puckey, LH	1
Hiyoshi, H; Ikuta, H; Ito, M; Kurusu, N; Okada, T; Saeki, T; Shinmyo, D; Tanaka, H; Tanaka, K; Yanagimachi, M; Yoshida, I	1
Kamaliah, MD; Sanjay, LD	1
Kanazawa, Y; Kawakami, M; Kawano, M; Kuroda, Y; Terao, M; Yaginuma, T	1
Inoue, M; Jimi, T; Machida, H; Niwa, Y; Wakayama, Y	1
Bosca, F; Fortea, JM; Janes, C; Latasa, JM; Millan, F; Miranda, MA; Serrano, G	1
Barbir, M; Hunt, B; Kehely, A; Kushwaha, S; Mitchell, A; Prescot, R; Thompson, GR; Yacoub, M	1
Branchi, A; Fasoli, A; Gandini, R; Maraffi, F; Montalto, C; Rovellini, A; Sommariva, D	1
Abukarshin, R; Ellias, N; Naschitz, JE; Yeshurun, D	1
Noacco, C; Taboga, C; Tonutti, L	1
Krishnamurthy, A; Thapar, GS	1
Garcia, RC; Nakandakare, E; Oliveira, HC; Quintão, EC; Rocha, JC; Sperotto, G	1
Arsenio, L; Rossi, A	1
Capaldo, B; Genovese, S; Mancini, M; Marotta, G; Patti, L; Postiglione, A; Riccardi, G; Rivellese, A; Saldalamacchia, G	1
González, G; Páez Moreno, JP	1
Lang, PD	1
Baker, FE; Walls, J; Williams, AJ	1
Pill, J; Schmidt, FH; Stegmeier, K; Wolff, S	1
Ikeda, S; Kusama, H; Nishiyama, M	1
Monk, JP; Todd, PA	1
Almér, LO; Kjellström, T	1
Faber, U; Keller, F; Reeck, S	1
Bartnikowska, E; Gwóźdź, E; Przybylski, R	1
Leiss, O; Meyer-Krahmer, K; von Bergmann, K	1
Aviram, M; Brook, J; Landman, L; Lanir, A; Yeshurun, D	1
Lang, PD; Oster, P; Schlierf, G; Vollmar, J	1
Berry, EM; Eisenberg, S; Gavish, D; Kleinman, Y; Leitersdorf, E; Norman, J; Witztum, E	1
Garanzelli, P; Melloni, GF; Melloni, R; Scarazatti, E	1

Reviews

26 review(s) available for bezafibrate and Hyperlipemia

Article	Year
The PPARs: from orphan receptors to drug discovery. Journal of medicinal chemistry, 2000, Feb-24, Volume: 43, Issue:4 Topics: Animals; Diabetes Mellitus; Drug Design; Humans; Hyperlipidemias; Hypertension; Inflammation; Ligands; Models, Molecular; Neoplasms; Nuclear Proteins; Obesity; Receptors, Cytoplasmic and Nuclear; Transcription Factors	2000
Effect of fibrates on lipid profiles and cardiovascular outcomes: a systematic review. The American journal of medicine, 2009, Volume: 122, Issue:10 Topics: Anticholesteremic Agents; Bezafibrate; Cardiovascular Diseases; Cholesterol, LDL; Clofibric Acid; Female; Fenofibrate; Gemfibrozil; Humans; Hyperlipidemias; Prognosis; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Treatment Outcome	2009
Second line options for hyperlipidemia management after cardiac transplantation. Cardiovascular therapeutics, 2013, Volume: 31, Issue:3 Topics: Azetidines; Bezafibrate; Diet; Exercise; Ezetimibe; Fish Oils; Heart Transplantation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Niacin	2013
[Syndrome X]. Nihon rinsho. Japanese journal of clinical medicine, 2002, Volume: 60 Suppl 10 Topics: Animals; Bezafibrate; Biguanides; Fatty Acids, Nonesterified; Humans; Hyperglycemia; Hyperinsulinism; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Resistance; Leptin; Life Style; Metabolic Syndrome; Pioglitazone; Thiazoles; Thiazolidinediones; Tumor Necrosis Factor-alpha	2002
A systematic review of the effectiveness of garlic as an anti-hyperlipidemic agent. Journal of the American Academy of Nurse Practitioners, 2003, Volume: 15, Issue:3 Topics: Anticholesteremic Agents; Bezafibrate; Cholesterol; Female; Garlic; Humans; Hyperlipidemias; Lipids; Male; Plants, Medicinal; Randomized Controlled Trials as Topic; Research Design; Treatment Outcome; Triglycerides	2003
Therapeutic implications of recent ATP III guidelines and the important role of combination therapy in total dyslipidemia management. Current opinion in cardiology, 2003, Volume: 18, Issue:4 Topics: Bezafibrate; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetic Angiopathies; Drug Therapy, Combination; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Metabolic Syndrome; Practice Guidelines as Topic	2003
[Lipoproteins HDL and coronary artery disease: a molecular mechanism of fibrate]. Przeglad lekarski, 2003, Volume: 60, Issue:4 Topics: Bezafibrate; Cholesterol, HDL; Cholesterol, LDL; Hepatocytes; Humans; Hyperlipidemias; Hypolipidemic Agents; Myocardial Ischemia; Receptors, Cytoplasmic and Nuclear; Transcription Factors; Up-Regulation	2003
Significance of high density lipoprotein-cholesterol in cardiovascular risk prevention: recommendations of the HDL Forum. American journal of cardiovascular drugs : drugs, devices, and other interventions, 2004, Volume: 4, Issue:5 Topics: Bezafibrate; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Niacin; Risk Assessment	2004
Prevention of cardiovascular events in diabetes. Clinical evidence, 2004, Issue:11 Topics: Angioplasty, Balloon; Antihypertensive Agents; Aspirin; Bezafibrate; Cardiovascular Diseases; Coronary Artery Bypass; Diabetic Angiopathies; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Hypolipidemic Agents; Platelet Glycoprotein GPIIb-IIIa Complex; Smoking Cessation	2004
Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons. Cardiovascular diabetology, 2005, Sep-16, Volume: 4 Topics: Bezafibrate; Cardiovascular Diseases; Cholesterol, HDL; Coronary Disease; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Myocardial Infarction; Peroxisome Proliferator-Activated Receptors; PPAR alpha; PPAR delta; PPAR gamma; Triglycerides	2005
[A case report of acute neuromyopathy induced by concomitant use of colchicine and bezafibrate]. No to shinkei = Brain and nerve, 2005, Volume: 57, Issue:9 Topics: Acute Disease; Aged; Bezafibrate; Colchicine; Drug Synergism; Drug Therapy, Combination; Electromyography; Gout; Humans; Hyperlipidemias; Hypolipidemic Agents; Kidney Failure, Chronic; Male; Neural Conduction; Neuromuscular Diseases	2005
Treatment of dyslipidaemias in patients with established vascular disease: a revival of the fibrates. Current medical research and opinion, 2000, Volume: 16, Issue:1 Topics: Bezafibrate; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Myocardial Ischemia; Randomized Controlled Trials as Topic; Triglycerides	2000
Concomitant suppression of hyperlipidemia and intestinal polyp formation by increasing lipoprotein lipase activity in Apc-deficient mice. Biological chemistry, 2006, Volume: 387, Issue:4 Topics: Age Factors; Animals; Benzamides; Bezafibrate; Cyclooxygenase 2; Genes, APC; Humans; Hyperlipidemias; Intestinal Polyps; Lipoprotein Lipase; Membrane Proteins; Mice; Organophosphorus Compounds; Pioglitazone; PPAR alpha; PPAR gamma; Thiazolidinediones; Triglycerides	2006
Prevention of cardiovascular events in diabetes. Clinical evidence, 2006, Issue:15 Topics: Angioplasty, Balloon; Antihypertensive Agents; Aspirin; Bezafibrate; Cardiovascular Diseases; Clopidogrel; Diabetic Angiopathies; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperglycemia; Hyperlipidemias; Hypertension; Hypolipidemic Agents; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Smoking Cessation; Ticlopidine	2006
Drug interactions with fibric acids. Pharmacology & therapeutics, 1994, Volume: 63, Issue:2 Topics: Anticoagulants; Bezafibrate; Clofibrate; Clofibric Acid; Contraceptives, Oral; Coronary Disease; Drug Interactions; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hyperlipidemias; Hypoglycemic Agents; Hypolipidemic Agents; Lipids	1994
A head-to-head comparison of the cost effectiveness of HMG-CoA reductase inhibitors and fibrates in different types of primary hyperlipidemia. Cardiovascular drugs and therapy, 1997, Volume: 10, Issue:6 Topics: Bezafibrate; Coronary Disease; Cost-Benefit Analysis; Double-Blind Method; Female; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemia, Familial Combined; Hyperlipidemias; Hypolipidemic Agents; Male	1997
Bezafibrate. An update of its pharmacology and use in the management of dyslipidaemia. Drugs, 1996, Volume: 52, Issue:5 Topics: Angina Pectoris; Apolipoproteins; Apolipoproteins A; Bezafibrate; Diabetes Complications; Drug Tolerance; Fibrinogen; Glucose; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Insulin Resistance; Lipoproteins; Male; Myocardial Infarction	1996
Pathophysiology and management of low high-density lipoprotein cholesterol. The American journal of cardiology, 1999, May-13, Volume: 83, Issue:9B Topics: Animals; Bezafibrate; Cholesterol, HDL; Coronary Disease; Diet; Female; Humans; Hyperlipidemias; Hypertriglyceridemia; Hypolipidemic Agents; Life Style; Lipoproteins, HDL; Male; Middle Aged; Risk Factors	1999
New developments in the treatment of low high-density lipoprotein cholesterol. Current atherosclerosis reports, 1999, Volume: 1, Issue:1 Topics: Bezafibrate; Cholesterol, HDL; Coronary Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Risk Factors	1999
Normocholesterolaemic dyslipidaemia: is there a role for fibrates? The Medical journal of Australia, 2001, Jan-15, Volume: 174, Issue:2 Topics: Bezafibrate; Clinical Trials as Topic; Coronary Disease; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents	2001
[BECAIT [Bezafibrate Coronary Atherosclerosis Intervention Trial]]. Nihon rinsho. Japanese journal of clinical medicine, 2001, Volume: 59 Suppl 3 Topics: Bezafibrate; Cholesterol, HDL; Coronary Artery Disease; Fibrinogen; Follow-Up Studies; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Myocardial Infarction; Randomized Controlled Trials as Topic; Triglycerides	2001
[Drug combination therapies for patients with hyperlipidemia and its significance]. Nihon rinsho. Japanese journal of clinical medicine, 2001, Volume: 59 Suppl 3 Topics: Anion Exchange Resins; Bezafibrate; Cholesterol, LDL; Cost-Benefit Analysis; Drug Therapy, Combination; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Niacin	2001
[Overviews of fibrate]. Nihon rinsho. Japanese journal of clinical medicine, 2001, Volume: 59 Suppl 3 Topics: Animals; Anticholesteremic Agents; Arteriosclerosis; Bezafibrate; Cholesterol, HDL; Cholesterol, LDL; Clofibrate; Coronary Disease; Diabetes Complications; Diabetes Mellitus; Humans; Hyperlipidemias; Hypolipidemic Agents; Randomized Controlled Trials as Topic; Triglycerides	2001
Disorders of lipid metabolism in patients with HIV disease treated with antiretroviral agents: frequency, relationship with administered drugs, and role of hypolipidaemic therapy with bezafibrate. The Journal of infection, 2001, Volume: 42, Issue:3 Topics: Bezafibrate; HIV Infections; HIV Protease Inhibitors; Humans; Hypercholesterolemia; Hyperlipidemias; Hypertriglyceridemia; Hypolipidemic Agents; Indinavir; Lipids; Retrospective Studies; Ritonavir; Saquinavir	2001
Photosensitivity induced by fibric acid derivatives and its relation to photocontact dermatitis to ketoprofen. Journal of the American Academy of Dermatology, 1992, Volume: 27, Issue:2 Pt 1 Topics: Aged; Bezafibrate; Cross Reactions; Dermatitis, Photoallergic; Drug Eruptions; Female; Fenofibrate; Humans; Hyperlipidemias; Ketoprofen; Male; Middle Aged; Patch Tests	1992
Bezafibrate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hyperlipidaemia. Drugs, 1987, Volume: 33, Issue:6 Topics: Animals; Bezafibrate; Humans; Hyperlipidemias	1987

Trials

41 trial(s) available for bezafibrate and Hyperlipemia

Article	Year
Therapy of Canine Hyperlipidemia with Bezafibrate. Journal of veterinary internal medicine, 2017, Volume: 31, Issue:3 Topics: Administration, Oral; Animals; Bezafibrate; Dog Diseases; Dogs; Female; Hyperlipidemias; Hypolipidemic Agents; Male; Prospective Studies; Treatment Outcome	2017
Pharmacoeconomic evaluation of anti-hyperlipidemic agent fenofibrate. Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 2002, Volume: 122, Issue:12 Topics: Aged; Bezafibrate; Cholesterol, LDL; Cost-Benefit Analysis; Female; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipids; Male; Middle Aged; Treatment Outcome	2002
Effects of hypolipidemic treatment on serum markers of vascular inflammation in dyslipidemic men. Medical science monitor : international medical journal of experimental and clinical research, 2003, Volume: 9, Issue:3 Topics: Adult; Bezafibrate; Biomarkers; Chemokine CCL2; E-Selectin; Gemfibrozil; Humans; Hyperlipidemias; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Hypolipidemic Agents; Inflammation Mediators; Lovastatin; Male; Middle Aged; Simvastatin; Vascular Cell Adhesion Molecule-1	2003
Bezafibrate improves hypertension and insulin sensitivity in humans. Hypertension research : official journal of the Japanese Society of Hypertension, 2003, Volume: 26, Issue:4 Topics: Adult; Apolipoproteins; Bezafibrate; Blood Glucose; Blood Pressure; Body Mass Index; Cell Membrane; Erythrocyte Membrane; Fatty Acids; Heart Rate; Humans; Hyperlipidemias; Hypertension; Hypolipidemic Agents; Insulin; Insulin Resistance; Lipids; Male	2003
[Comparative efficiency of prolonged diet and drug therapies for hyperlipidemias in patients with ischemic heart disease]. Klinicheskaia meditsina, 2004, Volume: 82, Issue:5 Topics: Aged; Bezafibrate; Cholesterol, LDL; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Myocardial Ischemia; Niacin; Time Factors	2004
Effect of anticholesterol therapy on soluble ICAM-1 in chronic stroke patients with hyperlipidemia. The Tokai journal of experimental and clinical medicine, 2005, Volume: 30, Issue:1 Topics: Aged; Anticholesteremic Agents; Bezafibrate; Cholesterol, HDL; Cholesterol, LDL; Chronic Disease; Female; Humans; Hyperlipidemias; Intercellular Adhesion Molecule-1; Male; Pravastatin; Solubility; Stroke; Triglycerides	2005
Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the management of dyslipidaemia. AIDS (London, England), 2005, Jul-01, Volume: 19, Issue:10 Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Bezafibrate; Cyclopropanes; Female; HIV Infections; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Nevirapine; Oxazines; Pravastatin; Protease Inhibitors; Reverse Transcriptase Inhibitors; Treatment Outcome	2005
Genetic variation in the hepatic lipase gene is associated with combined hyperlipidemia, plasma lipid concentrations, and lipid-lowering drug response. American heart journal, 2005, Volume: 150, Issue:6 Topics: Adult; Aged; Atorvastatin; Bezafibrate; Cytosine; Female; Genetic Variation; Genotype; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipase; Lipids; Lipoproteins; Male; Middle Aged; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Pyrroles; Reference Values; Thymine	2005
Effects of bezafibrate in patients with chronic hepatitis C virus infection: combination with interferon and ribavirin. Journal of viral hepatitis, 2006, Volume: 13, Issue:7 Topics: Adult; Aged; Antiviral Agents; Bezafibrate; Cholesterol, LDL; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Hyperlipidemias; Hypolipidemic Agents; Interferons; Male; Middle Aged; Pilot Projects; Prospective Studies; Ribavirin; RNA, Viral; Viremia	2006
Increase in circulating levels of adiponectin after treatment with statin and fibrate in patients with coronary artery disease and hyperlipidemia. Atherosclerosis, 2007, Volume: 193, Issue:2 Topics: Adiponectin; Aged; Atorvastatin; Bezafibrate; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pyrroles	2007
Fluvastatin improves arterial stiffness in patients with coronary artery disease and hyperlipidemia: a 5-year follow-up study. Circulation journal : official journal of the Japanese Circulation Society, 2008, Volume: 72, Issue:5 Topics: Aged; Aorta; Bezafibrate; Blood Flow Velocity; Coronary Artery Disease; Fatty Acids, Monounsaturated; Female; Fluvastatin; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Indoles; Linear Models; Male; Middle Aged; Multivariate Analysis; Prospective Studies; Pulsatile Flow; Risk Factors; Treatment Outcome	2008
[Therapeutic effects of bezafibrate in hyperlipidemia]. Casopis lekaru ceskych, 1983, May-20, Volume: 122, Issue:20 Topics: Adult; Aged; Bezafibrate; Clinical Trials as Topic; Clofibrate; Clofibric Acid; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged	1983
[Effect of bezafibrate on disorders of lipid metabolism]. Polski tygodnik lekarski (Warsaw, Poland : 1960), 1983, Dec-12, Volume: 38, Issue:50 Topics: Adult; Aged; Bezafibrate; Clinical Trials as Topic; Female; Humans; Hyperlipidemias; Hyperlipoproteinemia Type II; Hyperlipoproteinemias; Lipoproteins, LDL; Lipoproteins, VLDL; Male; Middle Aged; Triglycerides	1983
[Carbohydrate metabolism in bezafibrate therapy. Controlled study of glibenclamide-treated diabetics with hyperlipidemia]. MMW, Munchener medizinische Wochenschrift, 1982, May-28, Volume: 124, Issue:21 Topics: Aged; Bezafibrate; Carbohydrate Metabolism; Clinical Trials as Topic; Clofibrate; Clofibric Acid; Diabetes Complications; Diabetes Mellitus; Glyburide; Humans; Hyperlipidemias; Hypolipidemic Agents; Middle Aged; Patient Compliance	1982
Improvement of hyperlipidaemia by bezafibrate treatment in RDT patients. Proceedings of the European Dialysis and Transplant Association. European Dialysis and Transplant Association, 1981, Volume: 18 Topics: Adult; Bezafibrate; Cholesterol; Clinical Trials as Topic; Clofibrate; Clofibric Acid; Humans; Hyperlipidemias; Hypolipidemic Agents; Kidney Failure, Chronic; Middle Aged; Renal Dialysis; Triglycerides	1981
The effects of lipid lowering drugs on metabolic control and lipoprotein composition in type 2 diabetic patients with mild hyperlipidaemia. Diabetic medicine : a journal of the British Diabetic Association, 1995, Volume: 12, Issue:3 Topics: Apolipoproteins B; Bezafibrate; Blood Glucose; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Middle Aged; Phospholipids; Placebos; Pyrazines; Simvastatin; Triglycerides	1995
Improvement of glucose tolerance by bezafibrate in non-obese patients with hyperlipidemia and impaired glucose tolerance. Diabetes research and clinical practice, 1994, Volume: 25, Issue:3 Topics: Bezafibrate; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Follow-Up Studies; Glucose Intolerance; Glucose Tolerance Test; Humans; Hypercholesterolemia; Hyperlipidemias; Insulin; Male; Middle Aged; Pravastatin	1994
Comparison of lovastatin and bezafibrate on lipoprotein(a) plasma levels in cardiac transplant recipients. The American journal of cardiology, 1995, Mar-15, Volume: 75, Issue:8 Topics: Bezafibrate; Female; Heart Transplantation; Humans; Hyperlipidemias; Lipids; Lipoprotein(a); Lovastatin; Male; Middle Aged; Prospective Studies	1995
A randomized pilot trial of low-dose combination lipid-lowering therapy following coronary artery bypass grafting. Clinical cardiology, 1994, Volume: 17, Issue:2 Topics: Analysis of Variance; Bezafibrate; Colestipol; Coronary Artery Bypass; Double-Blind Method; Drug Therapy, Combination; Factor VII; Factor VIII; Female; Fibrinogen; Fibrinolysis; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Pilot Projects; Simvastatin	1994
Atherogenic risk reduction in patients with dyslipidaemia. comparison between bezafibrate and lovastatin. European heart journal, 1995, Volume: 16, Issue:11 Topics: Adult; Aged; Anticholesteremic Agents; Arteriosclerosis; Bezafibrate; Double-Blind Method; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Prospective Studies; Risk Factors	1995
[A comparison of bezafibrate and lovastatin treatment at the usual doses in post-heart transplant hyperlipemia]. Revista espanola de cardiologia, 1996, Volume: 49, Issue:12 Topics: Adult; Aged; Anticholesteremic Agents; Bezafibrate; Cross-Over Studies; Female; Heart Transplantation; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Lovastatin; Male; Middle Aged; Postoperative Complications	1996
A head-to-head comparison of the cost effectiveness of HMG-CoA reductase inhibitors and fibrates in different types of primary hyperlipidemia. Cardiovascular drugs and therapy, 1997, Volume: 10, Issue:6 Topics: Bezafibrate; Coronary Disease; Cost-Benefit Analysis; Double-Blind Method; Female; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemia, Familial Combined; Hyperlipidemias; Hypolipidemic Agents; Male	1997
Comparison of bezafibrate and simvastatin in the treatment of dyslipidaemia in patients with NIDDM. Diabetic medicine : a journal of the British Diabetic Association, 1997, Volume: 14, Issue:7 Topics: Aged; Apolipoproteins; Bezafibrate; Creatine Kinase; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Fibrinogen; Glycated Hemoglobin; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Lipoproteins; Lovastatin; Male; Middle Aged; Patient Compliance; Simvastatin	1997
Efficacy and tolerance of 400 MG bezafibrate in diabetic and hyperlipidaemic patients. Acta physiologica Hungarica, 1996, Volume: 84, Issue:4 Topics: Adolescent; Adult; Aged; Bezafibrate; Diabetes Mellitus, Type 2; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Risk Factors	1996
Comparison of bezafibrate versus lovastatin for lowering plasma insulin, fibrinogen, and plasminogen activator inhibitor-1 concentrations in hyperlipemic heart transplant patients. The American journal of cardiology, 1997, Oct-01, Volume: 80, Issue:7 Topics: Bezafibrate; Cross-Over Studies; Female; Fibrinogen; Heart Transplantation; Humans; Hyperlipidemias; Hypolipidemic Agents; Insulin; Lovastatin; Male; Middle Aged; Plasminogen Activator Inhibitor 1; Prospective Studies	1997
Evidence for a role of tumor necrosis factor alpha in disturbances of triglyceride and glucose metabolism predisposing to coronary heart disease. Metabolism: clinical and experimental, 1998, Volume: 47, Issue:1 Topics: Bezafibrate; Blood Glucose; Body Weight; Cholesterol; Coronary Artery Disease; Coronary Disease; Glucose; Homeostasis; Humans; Hyperlipidemias; Hypertriglyceridemia; Hypolipidemic Agents; Insulin; Insulin Resistance; Lipoproteins; Male; Middle Aged; Myocardial Infarction; Risk Factors; Triglycerides; Tumor Necrosis Factor-alpha	1998
[The effect of hypolipemic treatment on the pharmacokinetics of propranolol]. Annales Academiae Medicae Stetinensis, 1997, Volume: 43 Topics: Administration, Oral; Anticholesteremic Agents; Bezafibrate; Chromatography, High Pressure Liquid; Drug Interactions; Female; Humans; Hydroxylation; Hypercholesterolemia; Hyperlipidemias; Hypertriglyceridemia; Hypolipidemic Agents; Lovastatin; Male; Phenotype; Propranolol; Triglycerides	1997
Bezafibrate and lovastatin decrease the oxidizability of low-density lipoproteins in heart transplant recipients with hyperlidemia. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, 1998, Volume: 17, Issue:12 Topics: Bezafibrate; Cross-Over Studies; Female; Heart Transplantation; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins, LDL; Lovastatin; Male; Middle Aged; Oxidation-Reduction; Prospective Studies	1998
Long term improvement in dyslipidaemia in Type 2 diabetes with bezafibrate is not related to changes in insulin resistance. Atherosclerosis, 1999, Volume: 146, Issue:1 Topics: Bezafibrate; Diabetes Mellitus, Type 2; Follow-Up Studies; Humans; Hyperlipidemias; Hypolipidemic Agents; Insulin Resistance; Lipoproteins, HDL; Lipoproteins, LDL; Reference Values; Treatment Outcome	1999
Efficacy and tolerability of fluvastatin and bezafibrate in patients with hyperlipidemia and persistently high triglyceride levels. Journal of cardiovascular pharmacology, 2000, Volume: 35, Issue:3 Topics: Adult; Aged; Bezafibrate; Cholesterol; Double-Blind Method; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fluvastatin; Hemodynamics; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertriglyceridemia; Hypolipidemic Agents; Indoles; Male; Middle Aged	2000
Bezafibrate reduces blood glucose in type 2 diabetes mellitus. Metabolism: clinical and experimental, 2000, Volume: 49, Issue:3 Topics: Bezafibrate; Blood Glucose; Cholesterol; Cholesterol, HDL; Diabetes Mellitus, Type 2; Fasting; Female; Glycated Hemoglobin; Humans; Hyperlipidemias; Hypolipidemic Agents; Leptin; Male; Middle Aged; Triglycerides; Tumor Necrosis Factor-alpha	2000
Bezafibrate and simvastatin combination therapy for diabetic dyslipidaemia: efficacy and safety. Journal of internal medicine, 2000, Volume: 247, Issue:5 Topics: Aged; Bezafibrate; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Simvastatin; Time Factors; Treatment Outcome	2000
Chitotriosidase genotype and serum activity in subjects with combined hyperlipidemia: effect of the lipid-lowering agents, atorvastatin and bezafibrate. Metabolism: clinical and experimental, 2001, Volume: 50, Issue:4 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Atorvastatin; Bezafibrate; DNA; Double-Blind Method; Exons; Female; Genotype; Heptanoic Acids; Hexosaminidases; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Lipoproteins; Male; Middle Aged; Polymorphism, Genetic; Pyrroles	2001
Homocysteine elevation with fibrates: is it a class effect? The Israel Medical Association journal : IMAJ, 2001, Volume: 3, Issue:4 Topics: Adult; Bezafibrate; Clofibric Acid; Dietary Fats; Female; Fibric Acids; Homocysteine; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Triglycerides	2001
Maxepa versus bezafibrate in hyperlipidemic cardiac transplant recipients. The American journal of cardiology, 1992, Dec-15, Volume: 70, Issue:20 Topics: Apolipoprotein A-I; Apolipoproteins B; Bezafibrate; Cholesterol; Docosahexaenoic Acids; Drug Combinations; Eicosapentaenoic Acid; Fatty Acids, Omega-3; Female; Fish Oils; Heart Transplantation; Humans; Hyperlipidemias; Lipoprotein(a); Male; Time Factors; Triglycerides	1992
Effects of simvastatin, bezafibrate and gemfibrozil on the quantity and composition of plasma lipoproteins. Atherosclerosis, 1990, Volume: 85, Issue:2-3 Topics: Adult; Aged; Apolipoproteins; Bezafibrate; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Female; Gemfibrozil; Humans; Hydroxymethylglutaryl CoA Reductases; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins; Lovastatin; Male; Middle Aged; Simvastatin	1990
Effects of bezafibrate on insulin secretion and peripheral insulin sensitivity in hyperlipidemic patients with and without diabetes. Atherosclerosis, 1989, Volume: 75, Issue:2-3 Topics: Adult; Bezafibrate; Blood Glucose; Cholesterol; Diabetes Mellitus, Type 2; Female; Humans; Hyperlipidemias; Hyperlipoproteinemias; Insulin; Insulin Secretion; Male; Middle Aged; Triglycerides	1989
Comparative study of bezafibrate and probucol in hyperlipidaemia. Current medical research and opinion, 1989, Volume: 11, Issue:8 Topics: Adult; Aged; Bezafibrate; Clinical Trials as Topic; Dietary Fats; Female; Humans; Hyperlipidemias; Male; Middle Aged; Phenols; Probucol	1989
The fibrinolytic system and coagulation during bezafibrate treatment of hypertriglyceridemia. Atherosclerosis, 1986, Volume: 61, Issue:1 Topics: Adult; Bezafibrate; Blood Coagulation; Clinical Trials as Topic; Double-Blind Method; Fibrinolysis; Humans; Hyperlipidemias; Male; Middle Aged; Platelet Aggregation; Triglycerides	1986
Diurnal lipid and lipoprotein profiles in hypertriglyceridemic patients with bezafibrate and clofibrate. Research in experimental medicine. Zeitschrift fur die gesamte experimentelle Medizin einschliesslich experimenteller Chirurgie, 1986, Volume: 186, Issue:6 Topics: Adult; Aged; Bezafibrate; Circadian Rhythm; Clofibrate; Dietary Fats; Double-Blind Method; Female; Humans; Hyperlipidemias; Lipids; Lipoproteins; Male; Middle Aged; Triglycerides	1986
[Statistical analysis of variations in total cholesterol, HDL, HDL2, HDL3, LDL-cholesterol, VLDL-triglycerides, apo-A and apo-B lipoproteins in dyslipidemias during antilipemic therapy]. Bollettino della Societa italiana di biologia sperimentale, 1985, Jan-30, Volume: 61, Issue:1 Topics: Adult; Aged; Apolipoproteins; Bezafibrate; Cholesterol; Clinical Trials as Topic; Delayed-Action Preparations; Female; Humans; Hyperlipidemias; Lipoproteins; Male; Middle Aged; Triglycerides	1985

Other Studies

77 other study(ies) available for bezafibrate and Hyperlipemia

Article	Year
Maternally inherited diabetes and deafness coexists with lipoprotein lipase gene mutation-associated severe hyperlipidemia that was resistant to fenofibrate and atorvastatin, but sensitive to bezafibrate: A case report. Journal of diabetes investigation, 2022, Volume: 13, Issue:2 Topics: Atorvastatin; Bezafibrate; Deafness; Diabetes Mellitus, Type 2; Female; Fenofibrate; Humans; Hyperlipidemias; Lipoprotein Lipase; Mitochondrial Diseases; Mutation	2022
Novel PPAR pan agonist, ZBH ameliorates hyperlipidemia and insulin resistance in high fat diet induced hyperlipidemic hamster. PloS one, 2014, Volume: 9, Issue:4 Topics: Animals; Bezafibrate; Cricetinae; Diet, High-Fat; Drug Design; Gene Expression Regulation; Hyperinsulinism; Hyperlipidemias; Hypolipidemic Agents; Liver; Male; Muscle, Skeletal; Pentanoic Acids; PPAR alpha; Resveratrol; Sirtuin 1; Stilbenes; Triglycerides	2014
Synthesis of novel N-(4-benzoylphenyl)-2-furamide derivatives and their pharmacological evaluation as potent antihyperlipidemic agents in rats. Drug research, 2015, Volume: 65, Issue:3 Topics: Animals; Bezafibrate; Cholesterol, HDL; Furans; Hyperlipidemias; Hypolipidemic Agents; Male; Rats; Rats, Wistar; Triglycerides	2015
Beyond statins: assessing the alternatives. Some people can't tolerate statins, and others need additional medications to achieve healthy cholesterol levels. Harvard heart letter : from Harvard Medical School, 2014, Volume: 25, Issue:3 Topics: Anticholesteremic Agents; Azetidines; Bezafibrate; Cholesterol; Dietary Supplements; Exercise; Ezetimibe; Health Behavior; Health Promotion; Humans; Hyperlipidemias; Niacin	2014
Correlation between plasma levels of 7alpha-hydroxy-4-cholesten-3-one and cholesterol 7alpha-hydroxylation rates in vivo in hyperlipidemic patients. Steroids, 2008, Volume: 73, Issue:11 Topics: Aged; Anticholesteremic Agents; Bezafibrate; Cholestenones; Cholesterol; Cholesterol 7-alpha-Hydroxylase; Cholestyramine Resin; Complement C4; Data Interpretation, Statistical; Female; Gemfibrozil; Humans; Hypercholesterolemia; Hyperlipidemias; Hypolipidemic Agents; Kinetics; Male; Middle Aged; Reference Standards; Simvastatin	2008
The hypolipidemic activity of novel benzofuran-2-carboxamide derivatives in Triton WR-1339-induced hyperlipidemic rats: a comparison with bezafibrate. Journal of enzyme inhibition and medicinal chemistry, 2010, Volume: 25, Issue:6 Topics: Animals; Anthracenes; Atherosclerosis; Benzofurans; Bezafibrate; Cholesterol; Cholesterol, HDL; Detergents; Drug Design; Hyperlipidemias; Hypolipidemic Agents; Lipids; Male; Molecular Structure; Polyethylene Glycols; Random Allocation; Rats; Rats, Wistar; Time Factors; Triglycerides	2010
Synthesis and anti-hyperlipidemic evaluation of N‑(benzoylphenyl)-5-fluoro-1H-indole-2-carboxamide derivatives in Triton WR-1339-induced hyperlipidemic rats. Molecules (Basel, Switzerland), 2010, Aug-26, Volume: 15, Issue:9 Topics: Animals; Bezafibrate; Cholesterol, HDL; Hyperlipidemias; Hypolipidemic Agents; Indoles; Male; Polyethylene Glycols; Rats; Rats, Wistar; Structure-Activity Relationship	2010
Activation of peroxisome proliferator-activated receptor-α (PPARα) suppresses postprandial lipidemia through fatty acid oxidation in enterocytes. Biochemical and biophysical research communications, 2011, Jun-24, Volume: 410, Issue:1 Topics: Animals; Bezafibrate; Caco-2 Cells; Enterocytes; Fatty Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Mice; Mice, Inbred C57BL; Oxidation-Reduction; Postprandial Period; PPAR alpha; Triglycerides	2011
Antihyperlipidemic properties of novel N-(benzoylphenyl)-5-substituted-1H-indole-2-carboxamides in Triton WR-1339-induced hyperlipidemic rats. Molecules (Basel, Switzerland), 2011, Sep-29, Volume: 16, Issue:10 Topics: Animals; Bezafibrate; Cholesterol, HDL; Hyperlipidemias; Hypolipidemic Agents; Indoles; Male; Polyethylene Glycols; Rats; Rats, Wistar; Triglycerides	2011
[Focal myositis as a side effect of antilipidemics - 2 patients with involvement of the forearm]. Handchirurgie, Mikrochirurgie, plastische Chirurgie : Organ der Deutschsprachigen Arbeitsgemeinschaft fur Handchirurgie : Organ der Deutschsprachigen Arbeitsgemeinschaft fur Mikrochirurgie der Peripheren Nerven und Gefasse : Organ der V..., 2012, Volume: 44, Issue:1 Topics: Anticholesteremic Agents; Atorvastatin; Bezafibrate; Coronary Disease; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fluvastatin; Follow-Up Studies; Forearm; Heptanoic Acids; Humans; Hyperlipidemias; Image Interpretation, Computer-Assisted; Indoles; Magnetic Resonance Imaging; Male; Middle Aged; Muscle, Skeletal; Myositis; Pyrroles	2012
Effects of various fibrates on serum alkaline phosphatase activity. Atherosclerosis, 2002, Volume: 165, Issue:1 Topics: Alkaline Phosphatase; Bezafibrate; Clofibric Acid; Female; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Retrospective Studies; Treatment Outcome	2002
Frequency of creatine kinase elevation during treatment with fluvastatin in combination with fibrates (bezafibrate, fenofibrate, or gemfibrozil). The American journal of cardiology, 2003, Jan-15, Volume: 91, Issue:2 Topics: Adult; Bezafibrate; Creatine Kinase; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fenofibrate; Fluvastatin; Gemfibrozil; Humans; Hypercholesterolemia; Hyperlipidemias; Hypolipidemic Agents; Indoles; Male; Middle Aged	2003
Re: Gómez-Gerique, et al. Effect of atorvastatin and bezafibrate on plasma levels of C-reactive protein in combined (mixed) hyperlipidemia. Atherosclerosis 2002;162:245-51. Atherosclerosis, 2003, Volume: 166, Issue:1 Topics: Atorvastatin; Bezafibrate; C-Reactive Protein; Drug Interactions; Estrogen Replacement Therapy; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Pyrroles	2003
Effects of baseline level of triglycerides on changes in lipid levels from combined fluvastatin + fibrate (bezafibrate, fenofibrate, or gemfibrozil). The American journal of cardiology, 2003, Oct-01, Volume: 92, Issue:7 Topics: Age Factors; Bezafibrate; Drug Combinations; Fatty Acids, Monounsaturated; Female; Fenofibrate; Fluvastatin; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Indoles; Lipid Metabolism; Lipoproteins; Male; Middle Aged; Retrospective Studies; Sex Factors; Treatment Outcome; Triglycerides	2003
Concomitant suppression of hyperlipidemia and intestinal polyp formation in Apc-deficient mice by peroxisome proliferator-activated receptor ligands. Cancer research, 2003, Sep-15, Volume: 63, Issue:18 Topics: Age Factors; Animals; Bezafibrate; Cholesterol; Fatty Acids, Nonesterified; Genes, APC; Hyperlipidemias; Intestinal Polyposis; Intestine, Small; Ligands; Lipoprotein Lipase; Liver; Mice; Mice, Inbred C57BL; Mice, Knockout; Pioglitazone; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Thiazolidinediones; Transcription Factors; Triglycerides	2003
The sialic acid content of fibrinogen decreases during pregnancy and increases in response to fibrate therapy. Thrombosis research, 2005, Volume: 115, Issue:4 Topics: Bezafibrate; Case-Control Studies; Female; Fibrinogen; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; N-Acetylneuraminic Acid; Pregnancy; Protein Subunits; Spectrometry, Mass, Electrospray Ionization; Thrombin Time	2005
Elevated levels of remnant lipoproteins are associated with plasma platelet microparticles in patients with type-2 diabetes mellitus without obstructive coronary artery disease. European heart journal, 2006, Volume: 27, Issue:7 Topics: Angina Pectoris; Bezafibrate; Blood Platelets; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins; Male; Middle Aged; Risk Factors	2006
[Bezafibrate alone is an effective first-line therapy for primary sclerosing cholangitis: a case report]. Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2006, Volume: 103, Issue:6 Topics: Administration, Oral; Bezafibrate; Cholangitis, Sclerosing; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Middle Aged	2006
Severe decrease in serum HDL-cholesterol during combination therapy of bezafibrate and pioglitazone. Journal of atherosclerosis and thrombosis, 2006, Volume: 13, Issue:5 Topics: Bezafibrate; Cholesterol, HDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hyperlipidemias; Hypoglycemic Agents; Hypolipidemic Agents; Male; Middle Aged; Pioglitazone; Thiazolidinediones	2006
The short term effects of bezafibrate on the hypertriglyceridaemia of moderate to severe uraemia. British journal of clinical pharmacology, 1984, Volume: 18, Issue:3 Topics: Adult; Bezafibrate; Cholesterol; Creatine Kinase; Diet; Female; Humans; Hyperlipidemias; Insulin; Kidney Function Tests; Male; Middle Aged; Triglycerides; Uremia	1984
A therapeutic trial of bezafibrate on patients with hyperlipidemia with or without diabetes mellitus. Proceedings of the National Science Council, Republic of China. Part B, Life sciences, 1984, Volume: 8, Issue:3 Topics: Administration, Oral; Bezafibrate; Blood Glucose; Cholesterol; Diabetes Mellitus, Type 1; Double-Blind Method; Drug Evaluation; Glycated Hemoglobin; Humans; Hyperlipidemias; Random Allocation; Triglycerides	1984
Bezafibrate. Drug and therapeutics bulletin, 1983, Sep-23, Volume: 21, Issue:19 Topics: Bezafibrate; Cholesterol; Drug Evaluation; Humans; Hyperlipidemias; Triglycerides	1983
[Improvement in diabetes control by treatment with bezafibrate]. Deutsche medizinische Wochenschrift (1946), 1982, Oct-01, Volume: 107, Issue:39 Topics: Aged; Bezafibrate; Cholesterol; Clofibrate; Clofibric Acid; Diabetes Complications; Diabetes Mellitus; Female; Humans; Hyperlipidemias; Insulin; Male; Sulfonylurea Compounds; Triglycerides	1982
[Bezafibrate and delayed action etofibrate in hyperlipidemia]. Deutsche medizinische Wochenschrift (1946), 1983, Feb-25, Volume: 108, Issue:8 Topics: Bezafibrate; Body Weight; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Clofibrate; Clofibric Acid; Delayed-Action Preparations; Humans; Hyperlipidemias; Lipoproteins, HDL; Lipoproteins, LDL; Triglycerides	1983
[Bezafibrate in primary hyperlipidemias (author's transl)]. Klinische Wochenschrift, 1982, Jan-15, Volume: 60, Issue:2 Topics: Bezafibrate; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Clofibrate; Clofibric Acid; Female; Humans; Hyperlipidemias; Hyperlipoproteinemias; Lipoprotein Lipase; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged	1982
[What are the possibilities in the treatment of primary hyperlipidemia in diabetes mellitus?]. Die Medizinische Welt, 1982, Apr-30, Volume: 33, Issue:17 Topics: Bezafibrate; Clofibric Acid; Diabetes Complications; Humans; Hyperlipidemias; Hypolipidemic Agents	1982
Treatment of uremic hypertriglyceridaemia with bezafibrate. Atherosclerosis, 1982, Volume: 44, Issue:2 Topics: Bezafibrate; Cholesterol; Clofibrate; Clofibric Acid; Female; Humans; Hyperlipidemias; Kidney Failure, Chronic; Lipid Metabolism; Lipoproteins; Male; Triglycerides	1982
[Effect of bezafibrate on the carbohydrate metabolism of 17 diabetics with hyperlipidemia]. Die Medizinische Welt, 1981, Feb-20, Volume: 32, Issue:8 Topics: Anticholesteremic Agents; Bezafibrate; Body Weight; Carbohydrate Metabolism; Clofibrate; Clofibric Acid; Diabetes Complications; Humans; Hyperlipidemias; Placebos	1981
Clinical pharmacokinetics of bezafibrate in patients with impaired renal function. European journal of clinical pharmacology, 1981, Volume: 21, Issue:3 Topics: Adult; Aged; Bezafibrate; Clofibrate; Clofibric Acid; Creatinine; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Kidney Failure, Chronic; Kinetics; Male; Middle Aged	1981
Effect of lovastatin and bezafibrate on cyclosporine-induced hyperlipidemia in rabbits. Transplantation proceedings, 1995, Volume: 27, Issue:2 Topics: Animals; Bezafibrate; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cyclosporine; Hyperlipidemias; Kinetics; Lipoproteins; Lovastatin; Rabbits; Triglycerides	1995
Acute rhabdomyolysis and hemoglobin reduction after bezafibrate overdose in hyperlipidemic patients on hemodialysis. Nephron, 1994, Volume: 68, Issue:4 Topics: Acute Disease; Bezafibrate; Drug Overdose; Hemoglobins; Humans; Hyperlipidemias; Kidney Failure, Chronic; Male; Middle Aged; Renal Dialysis; Rhabdomyolysis	1994
Dual bezafibrate-simvastatin therapy for combined hyperlipidaemia. Journal of clinical pharmacy and therapeutics, 1994, Volume: 19, Issue:6 Topics: Adult; Aged; Bezafibrate; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides	1994
[Treatment of hyperlipidemia in obese patients: monotherapy versus bi-therapy]. Presse medicale (Paris, France : 1983), 1995, Jan-07, Volume: 24, Issue:1 Topics: Adult; Bezafibrate; Cholesterol; Cholesterol, HDL; Drug Evaluation; Drug Therapy, Combination; Humans; Hyperlipidemias; Male; Middle Aged; Obesity; Pravastatin; Triglycerides	1995
Lipid profiles on fibric-acid derivatives. Lancet (London, England), 1994, Sep-03, Volume: 344, Issue:8923 Topics: Bezafibrate; Cholesterol, HDL; Clofibric Acid; Female; Fibric Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids	1994
Bezafibrate-induced neutropenia. European journal of haematology, 1993, Volume: 50, Issue:3 Topics: Bezafibrate; Dyspnea; Female; Flushing; Humans; Hyperlipidemias; Hypertension; Leukocyte Count; Middle Aged; Neutropenia; Nifedipine; Urticaria	1993
Abnormal lipid profiles on fibrate derivatives. Lancet (London, England), 1996, Jan-27, Volume: 347, Issue:8996 Topics: Bezafibrate; Cholesterol, HDL; Clofibric Acid; Fibric Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids	1996
Effect of bezafibrate on HDL with APO A-I and APO A-II and on HDL with APO A-I without APO A-II in hyperlipidaemic patients. International journal of clinical pharmacology research, 1995, Volume: 15, Issue:4 Topics: Apolipoprotein A-I; Apolipoprotein A-II; Bezafibrate; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins, HDL; Male	1995
A lipid lowering drug (bezafibrate) has a favorable effect on liver enzymes (Al-P and gamma-GTP). Nihon Ika Daigaku zasshi, 1996, Volume: 63, Issue:5 Topics: Aged; Alkaline Phosphatase; Bezafibrate; Female; gamma-Glutamyltransferase; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipid Metabolism; Liver; Male	1996
Therapy and clinical trials. Current opinion in lipidology, 1996, Volume: 7, Issue:5 Topics: Arteriosclerosis; Bezafibrate; Cardiovascular Diseases; Clinical Trials as Topic; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Lipoproteins	1996
Bone scintigraphy of drug-induced rhabdomyolysis: antihyperlipidemia agent. Clinical nuclear medicine, 1996, Volume: 21, Issue:12 Topics: Bezafibrate; Bone and Bones; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Muscle, Skeletal; Radionuclide Imaging; Rhabdomyolysis	1996
Effect of bezafibrate on hypercoagulability assessed by fluorogenic prothrombin time in hyperlipidemic patients with non-insulin-dependent diabetes mellitus. Thrombosis research, 1997, Jun-15, Volume: 86, Issue:6 Topics: Aged; Bezafibrate; Blood Coagulation; Body Mass Index; Case-Control Studies; Cholesterol; Diabetes Mellitus, Type 2; Female; Fibrin Fibrinogen Degradation Products; Fibrinogen; Glycated Hemoglobin; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Male; Middle Aged; Plasminogen Activator Inhibitor 1; Prothrombin Time	1997
Paradoxical high-density lipoprotein reduction induced by fibrate therapy. Annals of clinical biochemistry, 1997, Volume: 34 ( Pt 5) Topics: Adult; Bezafibrate; Cholesterol, HDL; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Pyrazines	1997
Warfarin potentiation with bezafibrate. Postgraduate medical journal, 1997, Volume: 73, Issue:864 Topics: Aged; Anticoagulants; Bezafibrate; Blood Coagulation Disorders; Drug Synergism; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; International Normalized Ratio; Male; Warfarin	1997
Influence of apolipoprotein E polymorphism on bezafibrate treatment response in dyslipidemic patients. Journal of atherosclerosis and thrombosis, 1997, Volume: 4, Issue:1 Topics: Aged; Apolipoproteins E; Bezafibrate; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Male; Middle Aged; Phenotype; Polymorphism, Genetic	1997
Statin + fibrate combination therapy fluvastatin with bezafibrate or ciprofibrate in high risk patients with vascular disease. International journal of cardiology, 1999, Jun-01, Volume: 69, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Bezafibrate; Cardiovascular Diseases; Clofibric Acid; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fibric Acids; Fluvastatin; Humans; Hyperlipidemias; Hypolipidemic Agents; Indoles; Male; Middle Aged; Pilot Projects; Treatment Outcome	1999
Improved lipid lowering activity of bezafibrate following continuous gastrointestinal administration: pharmacodynamic rationale for sustained release preparation of the drug. Pharmaceutical research, 1999, Volume: 16, Issue:7 Topics: Animals; Bezafibrate; Cholesterol; Cholesterol, Dietary; Cholesterol, HDL; Delayed-Action Preparations; Disease Models, Animal; Drug Administration Routes; Duodenum; Enzyme Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipase; Lipids; Lipoproteins, HDL; Male; Polyethylene Glycols; Rats; Rats, Inbred Lew; Surface-Active Agents	1999
Plasma levels of E-selectin in normolipemic and hyperlipemic arteriopathic patients after vasoactive and lipid-lowering treatment. Minerva cardioangiologica, 2000, Volume: 48, Issue:3 Topics: Arterial Occlusive Diseases; Bezafibrate; E-Selectin; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Simvastatin; Vasoconstrictor Agents	2000
Beneficial changes in serum apo A-1 and its ratio to apo B and HDL in stable hyperlipidaemic subjects after Ramadan fasting in Kuwait. European journal of clinical nutrition, 2000, Volume: 54, Issue:6 Topics: Adult; Apolipoprotein A-I; Apolipoproteins B; Bezafibrate; Body Weight; Coronary Disease; Diabetes Complications; Diabetes Mellitus; Fasting; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Islam; Kuwait; Lipoproteins, HDL; Lovastatin; Male; Middle Aged	2000
Pharmacodynamic effects of bezafibrate and niacin combination: implications of the mode of administration. Journal of pharmaceutical sciences, 2000, Volume: 89, Issue:8 Topics: Animals; Bezafibrate; Cholesterol; Drug Therapy, Combination; Hyperlipidemias; Hypolipidemic Agents; Male; Niacin; Rats; Rats, Inbred Lew; Triglycerides	2000
A case for lipid-lowering? Diabetic medicine : a journal of the British Diabetic Association, 2000, Volume: 17 Suppl 2 Topics: Bezafibrate; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus, Type 2; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pravastatin; Risk Factors; Triglycerides	2000
Enhancement of preheparin serum lipoprotein lipase mass by bezafibrate administration. Atherosclerosis, 2000, Volume: 153, Issue:1 Topics: Bezafibrate; Drug Administration Schedule; Electrophoresis, Gel, Two-Dimensional; Enzyme-Linked Immunosorbent Assay; Humans; Hyperlipidemias; Hypertriglyceridemia; Hypolipidemic Agents; Lipids; Lipoprotein Lipase; Lipoproteins	2000
[Marked creatine-phosphokinase elevation in myopathy after treatment with bezafibrate]. Harefuah, 2000, Volume: 139, Issue:5-6 Topics: Adult; Bezafibrate; Creatine Kinase; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Middle Aged; Myositis	2000
Effects of fluvastatin and bezafibrate combination on plasma fibrinogen, t-plasminogen activator inhibitor and C reactive protein levels in coronary artery disease patients with mixed hyperlipidaemia (FACT Study)--a rebuttal. Thrombosis and haemostasis, 2001, Volume: 85, Issue:1 Topics: Bezafibrate; C-Reactive Protein; Coronary Disease; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hyperlipidemias; Hypolipidemic Agents; Indoles; Models, Statistical	2001
Effect of bezafibrate on soluble adhesion molecules and platelet activation markers in patients with connective tissue diseases and secondary hyperlipidemia. Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2001, Volume: 7, Issue:2 Topics: Bezafibrate; Biomarkers; Blood Platelets; Cell Adhesion Molecules; Connective Tissue Diseases; Female; Flow Cytometry; Humans; Hyperlipidemias; Lipids; Male; Middle Aged; Platelet Activation; Solubility	2001
Is pseudocholinesterase activity related to markers of triacylglycerol synthesis in Type II diabetes mellitus? Clinical science (London, England : 1979), 2001, Volume: 101, Issue:1 Topics: Aged; Anticholesteremic Agents; Apolipoproteins E; Bezafibrate; Biomarkers; Butyrylcholinesterase; Cross-Over Studies; Diabetes Mellitus, Type 2; Female; Humans; Hyperlipidemias; Hypoglycemic Agents; Insulin; Linear Models; Male; Phenotype; Pravastatin; Triglycerides	2001
Fibrate-induced increase in blood urea and creatinine. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2001, Volume: 16, Issue:7 Topics: Bezafibrate; Blood Urea Nitrogen; Clofibric Acid; Creatinine; Fenofibrate; Fibric Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Kidney Diseases	2001
Normocholesterolaemic dysslipidaemia: is there a role for fibrates? The Medical journal of Australia, 2001, Jun-04, Volume: 174, Issue:11 Topics: Bezafibrate; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Pyridines; Treatment Outcome; Triglycerides	2001
Variation at position 162 of peroxisome proliferator-activated receptor alpha does not influence the effect of fibrates on cholesterol or triacylglycerol concentrations in hyperlipidaemic subjects. Pharmacogenetics, 2001, Volume: 11, Issue:7 Topics: Aged; Amino Acid Substitution; Bezafibrate; Cholesterol; Female; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Random Allocation; Receptors, Cytoplasmic and Nuclear; Retrospective Studies; Transcription Factors; Triglycerides	2001
Squalene synthase inhibitors reduce plasma triglyceride through a low-density lipoprotein receptor-independent mechanism. European journal of pharmacology, 2001, Nov-23, Volume: 431, Issue:3 Topics: Animals; Atorvastatin; Bezafibrate; Cholesterol; Diphosphonates; Enzyme Inhibitors; Farnesyl-Diphosphate Farnesyltransferase; Hepatocytes; Heptanoic Acids; Hyperlipidemias; Hypolipidemic Agents; Lipids; Macaca mulatta; Molecular Structure; Pyrroles; Rabbits; Receptors, LDL; Triglycerides	2001
Rhabdomyolysis and acute renal failure following a switchover of therapy between two fibric acid derivatives. Singapore medical journal, 2001, Volume: 42, Issue:8 Topics: Acute Kidney Injury; Aged; Bezafibrate; Coronary Disease; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Kidney Diseases; Male; Rhabdomyolysis	2001
Marked removal of bezafibrate-induced high-density lipoprotein-cholesterol by low-density lipoprotein apheresis. Clinica chimica acta; international journal of clinical chemistry, 2002, Volume: 318, Issue:1-2 Topics: Aged; Apolipoproteins E; Arteriosclerosis Obliterans; Bezafibrate; Blood Component Removal; Cholesterol, HDL; Diabetes Mellitus, Type 2; Electrophoresis, Agar Gel; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins; Lipoproteins, LDL; Male	2002
[Bezafibrate myopathy in two patients with chronic renal failure]. Rinsho shinkeigaku = Clinical neurology, 1992, Volume: 32, Issue:7 Topics: Aged; Bezafibrate; Humans; Hyperlipidemias; Kidney Failure, Chronic; Male; Middle Aged; Molecular Weight; Rhabdomyolysis	1992
Effects of slow release bezafibrate on the lipid pattern and on blood glucose of type 2 diabetic patients with hyperlipidaemia. Pharmacological research, 1992, Volume: 25, Issue:3 Topics: Aged; Bezafibrate; Blood Glucose; Cholesterol; Diabetes Mellitus, Type 2; Female; Fructosamine; Hemoglobins; Hexosamines; Humans; Hyperlipidemias; Lipids; Lipoproteins, HDL; Male; Middle Aged; Triglycerides	1992
[Long-term bezafibrate treatment in a lipid clinic]. Harefuah, 1992, May-15, Volume: 122, Issue:10 Topics: Bezafibrate; Cholesterol; Humans; Hyperlipidemias; Triglycerides	1992
[Comparison of the efficacy of pantethine, acipimox, and bezafibrate on plasma lipids and index of cardiovascular risk in diabetics with dyslipidemia]. Minerva medica, 1991, Volume: 82, Issue:10 Topics: Bezafibrate; Cardiovascular Diseases; Diabetes Complications; Humans; Hyperlipidemias; Hypolipidemic Agents; Pantetheine; Pyrazines; Risk Factors	1991
Effect of bezafibrate & nicotinic acid on triton induced hyperlipidemias in CFY rats. The Indian journal of medical research, 1991, Volume: 94 Topics: Animals; Bezafibrate; Cholesterol; Drug Therapy, Combination; Hyperlipidemias; Male; Niacin; Polyethylene Glycols; Rats; Triglycerides	1991
[Efficacy of blood lipid normalization and tolerance in dyslipidemic patients treated for 18 months with fibric acid derivatives]. La Clinica terapeutica, 1989, Dec-31, Volume: 131, Issue:6 Topics: Adult; Bezafibrate; Drug Evaluation; Female; Fenofibrate; Gemfibrozil; Humans; Hyperlipidemias; Lipids; Male; Middle Aged; Propionates; Time Factors	1989
Bezafibrate in the treatment of hyperlipidemia. Boletin de la Asociacion Medica de Puerto Rico, 1989, Volume: 81, Issue:2 Topics: Bezafibrate; Humans; Hyperlipidemias	1989
The effect of bezafibrate on hyperlipidaemia in experimental nephrotic syndrome in rats. The Journal of pharmacy and pharmacology, 1985, Volume: 37, Issue:10 Topics: Animals; Bezafibrate; Blood Proteins; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Hyperlipidemias; Nephrotic Syndrome; Protein Binding; Rats; Rats, Inbred Strains; Time Factors; Triglycerides	1985
[Diabetes and hyperlipidemia. Increased coronary risk can be prevented]. Fortschritte der Medizin. Supplement : die Kongressinformation fur die Praxis, 1988, Volume: 46 Topics: Bezafibrate; Coronary Disease; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias	1988
Effect of bezafibrate on serum lipids in normo- and spontaneously hyperlipidemic rats. Methods and findings in experimental and clinical pharmacology, 1988, Volume: 10, Issue:8 Topics: Animals; Bezafibrate; Cholesterol; Hyperlipidemias; Lipids; Male; Rats; Rats, Inbred F344; Rats, Inbred Strains; Rats, Inbred WKY; Triglycerides	1988
[Pharmacological investigation of bezafibrate, a hypolipidemic agent (1). Effects of bezafibrate on normal and experimental hyperlipidemia in rats]. Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 1988, Volume: 92, Issue:3 Topics: Administration, Oral; Animals; Bezafibrate; Cholesterol, Dietary; Depression, Chemical; Fructose; Hyperlipidemias; Male; Polyethylene Glycols; Rats; Triglycerides	1988
Effect of toxicity of bezafibrate in hemodialysis patients. Clinical nephrology, 1987, Volume: 28, Issue:3 Topics: Bezafibrate; Humans; Hyperlipidemias; Renal Dialysis	1987
[Evaluation of treatment for retinal blood flow insufficiency in hyperlipidemia]. Polski tygodnik lekarski (Warsaw, Poland : 1960), 1986, Apr-14, Volume: 41, Issue:15 Topics: Adult; Aged; Bezafibrate; Female; Humans; Hyperlipidemias; Male; Middle Aged; Regional Blood Flow; Retinal Diseases; Retinal Vessels	1986
Biliary lipid secretion in patients with heterozygous familial hypercholesterolemia and combined hyperlipidemia. Influence of bezafibrate and fenofibrate. Journal of lipid research, 1986, Volume: 27, Issue:7 Topics: Adult; Bezafibrate; Bile; Bile Acids and Salts; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Fenofibrate; Humans; Hyperlipidemias; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lipid Metabolism; Liver; Male; Middle Aged; Phospholipids; Propionates; Triglycerides	1986
[Treatment of hyperlipidemia with bezafibrate]. Harefuah, 1986, Dec-01, Volume: 111, Issue:11 Topics: Bezafibrate; Humans; Hyperlipidemias	1986
Bulimia. An underlying behavioral disorder in hyperlipidemic pancreatitis: a prospective multidisciplinary approach. Archives of internal medicine, 1987, Volume: 147, Issue:4 Topics: Adult; Bezafibrate; Bulimia; Cholesterol; Female; Humans; Hyperlipidemias; Lipoprotein Lipase; Male; Middle Aged; Pancreatitis; Prospective Studies; Triglycerides	1987